Guggenheim Initiates Coverage On Vera Therapeutics with Buy Rating, Announces Price Target of $27
Portfolio Pulse from richadhand@benzinga.com
Guggenheim analyst Vamil Divan has initiated coverage on Vera Therapeutics with a Buy rating and a price target of $27.
August 16, 2023 | 8:44 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vera Therapeutics has received a Buy rating from Guggenheim with a price target of $27.
The Buy rating and price target set by Guggenheim indicate a positive outlook for Vera Therapeutics. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100